Well, yesterday was a start that ended in a whimper. We have had these little starts to a recovery before, but they barely lasted more than a couple of days. I sort of wonder if we are now in a new range with $98 as the upper boundary. That would not be the worst scenario […]
March 26th Biotech Update
So a whole lot of nothing yesterday. While I guess it remains good that support is holding, we really need to be building some momentum or, perhaps, we would like to see the sector build some momentum. The sector is certainly in a better place than last year and ultimately, I think we do get […]
March 25th Biotech Update
While the sector certainly seems to be holding up around support, this does not feel like a good place for the sector. The market and tech sectors are at highs and we are struggling to bounce off of what should be pretty strong levels of support. The small caps are not doing as well as […]
March 21st Biotech Update
Nothing really that news worthy this week so far. That being said the sector might be getting some momentum. We definitely needed to some bouncing after the hanging around what should be support and so far we seem to be seeing that bounce. The chart itself is showing a nice two day move and ideally […]
Mailing List
Introduction
Overview
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.